Literature DB >> 34083846

Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measures.

Ksenia Kasianova1, Mark Kelbert1, Pavel Mozgunov2.   

Abstract

In many rare disease Phase II clinical trials, two objectives are of interest to an investigator: maximising the statistical power and maximising the number of patients responding to the treatment. These two objectives are competing, therefore, clinical trial designs offering a balance between them are needed. Recently, it was argued that response-adaptive designs such as families of multi-arm bandit (MAB) methods could provide the means for achieving this balance. Furthermore, response-adaptive designs based on a concept of context-dependent (weighted) information criteria were recently proposed with a focus on Shannon's differential entropy. The information-theoretic designs based on the weighted Renyi, Tsallis and Fisher informations are also proposed. Due to built-in parameters of these novel designs, the balance between the statistical power and the number of patients that respond to the treatment can be tuned explicitly. The asymptotic properties of these measures are studied in order to construct intuitive criteria for arm selection. A comprehensive simulation study shows that using the exact criteria over asymptotic ones or using information measures with more parameters, namely Renyi and Tsallis entropies, brings no sufficient gain in terms of the power or proportion of patients allocated to superior treatments. The proposed designs based on information-theoretical criteria are compared to several alternative approaches. For example, via tuning of the built-in parameter, one can find designs with power comparable to the fixed equal randomisation's but a greater number of patients responded in the trials.
© 2021 The Author(s).

Entities:  

Keywords:  Experimental design; Information gain; Phase II clinical trial; Small population trials; Weighted information

Year:  2021        PMID: 34083846      PMCID: PMC7985674          DOI: 10.1016/j.csda.2021.107187

Source DB:  PubMed          Journal:  Comput Stat Data Anal        ISSN: 0167-9473            Impact factor:   1.681


  9 in total

1.  Randomized play-the-winner clinical trials: review and recommendations.

Authors:  W F Rosenberger
Journal:  Control Clin Trials       Date:  1999-08

2.  TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Authors:  Ruitao Lin; Robert L Coleman; Ying Yuan
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

3.  The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research.

Authors:  Benjamin Djulbegovic
Journal:  Cancer Control       Date:  2009-10       Impact factor: 3.302

4.  Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.

Authors:  Ruitao Lin; Ying Yuan
Journal:  Biostatistics       Date:  2020-10-01       Impact factor: 5.899

5.  Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.

Authors:  Sofía S Villar; Jack Bowden; James Wason
Journal:  Stat Sci       Date:  2015       Impact factor: 2.901

6.  A Bayesian adaptive design for clinical trials in rare diseases.

Authors:  S Faye Williamson; Peter Jacko; Sofía S Villar; Thomas Jaki
Journal:  Comput Stat Data Anal       Date:  2016-09-28       Impact factor: 1.681

7.  Covariate-adjusted response-adaptive randomization for multi-arm clinical trials using a modified forward looking Gittins index rule.

Authors:  Sofía S Villar; William F Rosenberger
Journal:  Biometrics       Date:  2017-07-06       Impact factor: 2.571

8.  An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicity.

Authors:  Pavel Mozgunov; Thomas Jaki
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-15       Impact factor: 1.864

9.  Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.

Authors:  Sofía S Villar; James Wason; Jack Bowden
Journal:  Biometrics       Date:  2015-06-22       Impact factor: 2.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.